Free exam prep

BCSCP Board Certified Sterile Compounding Pharmacist

5.3 Category 3 Beyond-Use Dating: Requirements for Extended Dating (60/90/120 Days)

Q: A compounding facility has satisfied all facility, engineering, personnel qualification, stability-indicating analytical testing, container-closure integrity, and batch release testing requirements for Category 3 compounding. The facility manufactures a batch of sterile injectable solution that undergoes terminal moist heat sterilization. Under the 2023 revision of USP , what is the maximum beyond-use date that may be assigned to this terminally sterilized Category 3 CSP when stored in a frozen state (-25°C to -10°C)?

180 days. Under the 2023 revision of USP General Chapter (Table 14), the maximum beyond-use dates for Category 3 compounded sterile preparations that undergo terminal sterilization and pass all required release testing are: 90 days at controlled room temperature (20^\circ\text{C to }25^\circ\text{C}), 120 days under refrigeration (2^\circ\text{C to }8^\circ\text{C}), and 180 days in a frozen state (-25^\circ\text{C to }-10^\circ\text{C}). For aseptically prepared Category 3 CSPs that pass sterility testing, the corresponding limits are 60 days room temperature, 90 days refrigerated, and 120 days frozen.

Key Takeaways

Category 3 CSPs may be dated beyond Category 2 limits, up to 60 days at room temperature, 90 days refrigerated and 120 days frozen if aseptically processed, or 90/120/180 days if terminally sterilized.
Every Category 3 batch must be sterility tested (USP <71> or a validated alternative), and any batch that requires sterility testing is capped at 250 final yield units.
The BUD must be supported by stability data from a stability-indicating method for the exact formulation and container-closure materials. Published or unpublished studies qualify only if they match exactly.
Category 3 compounders repeat garbing and aseptic manipulation competencies at least every 3 months.
A Category 3 facility also needs sterile low-lint outer garb with no exposed skin, monthly air sampling, weekly surface sampling (plus the PEC after each batch), and weekly sporicidal disinfection.

Last updated: September 2026

The Category 3 High-Reliability Compounding Tier

In specialized health-system pharmacies, home infusion establishments, and ophthalmology compounding practices, clinical necessity often demands beyond-use dates that exceed the standard Category 2 default thresholds (for example, a 60-day refrigerated BUD for batch-prepared syringes or bags used in home infusion or ophthalmology).

To assign these extended dates, USP General Chapter <797> establishes the Category 3 CSP tier. Category 3 is not an architectural classification, but a comprehensive, intensified quality assurance regime that validates both chemical stability and continuous sterility assurance over long storage durations.

Maximum Allowable Category 3 BUD Limits

Compounding & Sterilization Method	Controlled Room Temp ( $20^\circ\text{C}$ to $25^\circ\text{C}$ )	Refrigerated ( $2^\circ\text{C}$ to $8^\circ\text{C}$ )	Frozen ( $-25^\circ\text{C}$ to $-10^\circ\text{C}$ )
Aseptically processed CSP	Up to 60 days	Up to 90 days	Up to 120 days
Terminally sterilized CSP	Up to 90 days	Up to 120 days	Up to 180 days

Warning

These timeframes represent absolute compendial ceilings. Under no circumstances may a facility assign a BUD exceeding 120 days for an aseptically processed CSP or 180 days for a terminally sterilized CSP, even if chemical stability data exists for 1 year.

Mandatory Prerequisites for Category 3 Compounding

To assign a Category 3 BUD, a facility must meet every requirement in USP <797> Section 14.4 at all times, not just on the days it makes Category 3 CSPs (USP FAQ):

Cleanroom Suite Required: Category 3 CSPs are made in an ISO Class 5 PEC in an ISO Class 7 buffer room with an anteroom, or in a pharmaceutical isolator in an ISO Class 8 or better room. They can never be made in a Segregated Compounding Area (SCA).
Batch Sterility Testing: Every Category 3 batch must be sterility tested per USP <71>, by membrane filtration or direct inoculation, or by a validated alternative that is non-inferior (USP <1223>). Batches are capped at 250 final yield units. If a CSP is dispensed before results are known, the notification and recall procedures in USP <797> 18.1 must be ready.
Bacterial Endotoxin Testing: Injectable Category 3 CSPs made from any nonsterile component must pass bacterial endotoxin testing (USP <85>).
Stability Data: The facility must have stability data from a validated stability-indicating method, such as HPLC that separates intact drug from its degradation products. The study must use the exact formulation (ingredients of identical grade and procedure) and container-closure materials, and it may be published or unpublished. It does not need to be repeated for each batch.
Environmental Monitoring and Cleaning: Viable air sampling within 30 days before starting and then monthly; surface sampling weekly, plus inside the PEC after each batch; a sporicidal disinfectant applied at least weekly.
Quarterly Personnel Qualification: Category 3 compounders repeat the garbing competency and the aseptic manipulation competency (media fill, gloved fingertip sample and direct compounding area surface sample) at least every 3 months.
Sterile Garbing with No Exposed Skin: All low-lint outer garb in the Category 3 buffer room is sterile, and the face and neck are covered. Goggles and respirators need not be sterile but must be disinfected per SOP.

Analytical Stability Testing: Stability-Indicating Assays (SIA) & Forced Degradation

USP <797> requires Category 3 BUDs to rest on a stability-indicating analytical method. The method must distinguish the active ingredient from its degradants and impurities, for example as shown by forced degradation studies, and it must quantify the drug. It is validated using characteristics such as those in USP <1225>. The facility must keep documentation of the study: methodology, method validation and all results. Extrapolation, or a method such as simple UV absorbance that cannot tell drug from degradant, does not qualify.

Chromatographic Separation: An SIA (typically HPLC-DAD or LC-MS/MS) physically separates the intact parent drug molecule from all degradation products, excipients, and impurities.
Forced Degradation (Stress Testing): Typical laboratory practice stresses the drug with acid, base, oxidation, heat and light. The goal is to show that the degradation products separate from the parent peak, with adequate resolution and peak purity.

Container-Closure Integrity Testing (CCIT) Methodologies

A preparation stored for up to 120 or 180 days depends on its seal the whole time. USP <1207> describes container closure integrity (CCI) testing. USP <797> requires CCI evaluation for multiple-dose CSP containers, and USP's FAQ lists closure integrity among factors to weigh when assigning long BUDs. It is not, however, a separately listed Category 3 release test. The methods in USP <1207> include:

Deterministic CCIT Methods: USP <1207> favors deterministic, non-destructive quantitative testing over legacy dye ingress.
High-Voltage Leak Detection (HVLD): Detects micro-cracks and pinholes down to sub-micron dimensions ( $< 1\,\mu\text{m}$ ) in liquid-filled parenteral vials.
Vacuum Decay Testing (ASTM F2338): Hermetically evacuates a test chamber and measures pressure rise from escaping vapor, detecting leaks down to $1\text{ to }2\,\mu\text{m}$ .
Frequency Modulation Spectroscopy (FMS): Laser-based headspace gas analysis measuring oxygen or carbon dioxide ingress over time.

Release Testing for Category 3 Batches

Test	USP <797> status for Category 3	Key facts
Visual inspection (<797> 12.1)	Required for every CSP	Particulates, discoloration, container closure defects, label match
Sterility (USP <71>)	Required for every batch	14 days in Fluid Thioglycollate Medium and Soybean-Casein Digest Medium, or a validated alternative; batch 250 units maximum
Bacterial endotoxins (USP <85>)	Required for injectables with any nonsterile component	Limit $= \frac{K}{M}$ ; $K = 5.0\,\text{EU/kg}$ parenteral, $0.2\,\text{EU/kg}$ intrathecal
Subvisible particulates (USP <788>)	Not a listed <797> release test	Large-volume (> 100 mL): $\le 25$ /mL $\ge 10\,\mu\text{m}$ and $\le 3$ /mL $\ge 25\,\mu\text{m}$ ; small-volume: $\le 6{,}000$ and $\le 600$ per container
Potency assay	Not a listed per-batch <797> test (the stability study supports the BUD)	Many facilities test potency anyway as a quality control

Test Your Knowledge

A 503A pharmacy wants 90-day refrigerated BUDs for an aseptically prepared, preservative-free hydromorphone and bupivacaine epidural solution. Which set of requirements does USP <797> impose for Category 3 dating?

An ISO Class 5 PEC in an ISO Class 7 buffer room, semiannual media fills, and the manufacturer's package insert

A laminar airflow workbench in an unclassified room, continuous particle counting, and quarterly fingertip testing

Sterile low-lint garb with no exposed skin; competency every 3 months; monthly air and weekly surface sampling (plus the PEC after each batch); weekly sporicidal use; sterility testing of each batch; and stability-indicating data

Annual personnel qualification, terminal autoclaving of the bags, daily air sampling, and literature for a different concentration

Test Your Knowledge

A compounding facility has satisfied all facility, engineering, personnel qualification, stability-indicating analytical testing, container-closure integrity, and batch release testing requirements for Category 3 compounding. The facility manufactures a batch of sterile injectable solution that undergoes terminal moist heat sterilization. Under the 2023 revision of USP <797>, what is the maximum beyond-use date that may be assigned to this terminally sterilized Category 3 CSP when stored in a frozen state (-25°C to -10°C)?

60 days

90 days

120 days

180 days

Test Your Knowledge

A facility makes a batch of 50 intrathecal baclofen cassettes from nonsterile baclofen powder and plans to assign a Category 3 BUD. Beyond visual inspection, which release tests does USP <797> require?

A sterility test on the batch and a bacterial endotoxin test

pH only, with sterility testing on a random quarterly sample

A sterility test only, because endotoxin testing is optional for intrathecal CSPs

A 48-hour rapid screen, with sterility testing deferred until after every unit is dispensed

Sections you finish are checked off in the contents.

Up Next

5.4 Container Types, Puncture Limits & Multi-Dose Container Rules

Continue learning